Coherus Rolls Out YUSIMRY At $995 Per Carton In US

RTTNews | 854 dias atrás
Coherus Rolls Out YUSIMRY At $995 Per Carton In US

(RTTNews) - Coherus BioSciences, Inc. (CHRS) announced Monday that YUSIMRY (adalimumab-aqvh) is now available for commercial sale in the United States at a list price of $995 per carton for two 40 mg/0.8 mL autoinjectors.

The pricing represents a discount of more than 85% to Humira (adalimumab), currently priced at $6,922 per carton of two pens.

YUSIMRY is presented in a state-of-the-art autoinjector and includes Coherus' proprietary non-stinging, citrate-free formulation and a 29-gauge needle.

YUSIMRY, approved in 2021 by the U.S. Food and Drug Administration, is a tumor necrosis factor blocker indicated to reduce the signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, and to treat Crohn's disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa.

YUSIMRY Solutions - Coherus' patient services platform - will ensure improved access and a fast and seamless experience as patients start or switch to YUSIMRY treatment based on a determination by their healthcare provider.

Etiquetas: CHRS
read more
Coherus, Junshi Biosciences Say FDA Accepts Resubmission Of Toripalimab BLA

Coherus, Junshi Biosciences Say FDA Accepts Resubmission Of Toripalimab BLA

Coherus BioSciences, Inc. (CHRS) and Shanghai Junshi Biosciences Co., Ltd. announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) resubmission for toripalimab in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma (NPC) and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy.
RTTNews | 1216 dias atrás
Bay Street Likely To Open On Positive Note

Bay Street Likely To Open On Positive Note

Canadian shares are likely to open higher Monday morning, with firm metal prices expected to trigger buying in the materials sector. The focus will be on the developments on the trade front and corporate earnings announcements.
RTTNews | 1 h 57 min atrás
UK Manufacturing PMI At 1-Year High

UK Manufacturing PMI At 1-Year High

The UK manufacturing activity shrank in October but the pace of contraction was the slowest in a year, the final purchasing managers' survey from S&P Global revealed on Monday. The factory Purchasing Managers' Index rose to a 12-month high of 49.7 in October from 46.2 in September. The flash reading was 49.6.
RTTNews | 2 h 30 min atrás
Eurozone Manufacturing Sector Stagnates In October

Eurozone Manufacturing Sector Stagnates In October

Eurozone manufacturing sector stagnated in October, as initially estimated, following a fractional deterioration in September, the purchasing managers' survey compiled by S&P Global showed on Monday. The final Purchasing Managers' Index posted 50.0 in October, signalling no change in the operating conditions in the manufacturing sector. The score matched the initial estimate and remained above S
RTTNews | 3 h 2 min atrás
FTSE 100 Up Marginally In Cautious Trade

FTSE 100 Up Marginally In Cautious Trade

U.K.'s stock market's FTSE 100 is gaining some ground in positive territory on Monday, with stocks from the banking sector attracting attention ahead of the Bank of England's monetary policy announcement this week.
RTTNews | 3 h 21 min atrás
Fed's Hawkish Guidance Lifts Dollar

Fed's Hawkish Guidance Lifts Dollar

A drastic reduction in Fed rate cut hopes in the aftermath of the hawkish forward guidance by Chair Jerome Powell boosted the U.S. Dollar during the week ended October 31.
RTTNews | 3 h 31 min atrás